Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy

Robert A Bradway is Chairman, CEO and President at Amgen. OQRO lists 14 transactions filed with the SEC under this name, the latest on Jul 6, 2026, each linked to the official Form 4.
Chairman, CEO and President
Photo: Amgen, Inc., CC BY-SA 4.0. Original file
Disclosures on record
14
Companies involved
2
BoeingBA
3 disclosures · Jan 2026 – Jul 2026
Jul 1, 2026406disclosed Jul 6
DetailsOfficial recordApr 1, 2026428disclosed Apr 3
DetailsOfficial recordJan 2, 2026400disclosed Jan 6
DetailsOfficial recordAmgenAMGN
11 disclosures · Mar 2026 – May 2026
May 7, 20262,079disclosed May 11
DetailsOfficial recordMay 5, 202679Kdisclosed May 8
DetailsOfficial recordMay 5, 202612Kdisclosed May 8
DetailsOfficial recordMay 6, 20261,702disclosed May 8
DetailsOfficial recordMay 2, 20262,631disclosed May 5
DetailsOfficial recordMay 2, 20262,426disclosed May 5
DetailsOfficial recordMar 16, 202621Kdisclosed Mar 19
DetailsOfficial recordMar 4, 2026120Kdisclosed Mar 7
DetailsOfficial recordMar 4, 2026120Kdisclosed Mar 7
DetailsOfficial recordMar 4, 202684Kdisclosed Mar 7
DetailsOfficial recordMar 3, 202643Kdisclosed Mar 6
DetailsOfficial recordRobert A Bradway bought shares on the open market in 2014, and has not bought since 2014. Sales in 2 of the 13 years since 2014.
Robert A Bradway reported 1 open-market purchase and 2 sales since 2014; purchases in 2014.
| Year | Bought | Sold |
|---|---|---|
| 2016 | — | $2.93M1×1 trade |
| 2015 | — | $3.36M1×1 trade |
| 2014 | $100K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Robert A Bradway reported holding 505,160 shares of Amgen (AMGN), worth about $222M at the last close of $439 (Nov 19, 2026).
Amgen's proxy statement reports total compensation of $24.7M for Robert A Bradway for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 7, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Amgen AMGN | 505,160 | 505K direct | $439 | $222M | May 7, 2026 |
Is this Robert A Bradway’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated May 7, 2026, Robert A Bradway reported holding 505,160 shares of Amgen (AMGN). At the last close of $439 on Nov 19, 2026, that is about $222M. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert A Bradway's net worth. What SEC Form 4 shows is the stock stake: 505,160 shares of Amgen (AMGN), about $222M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Amgen's proxy statement reports total compensation of $24.7M for Robert A Bradway for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Robert A Bradway bought shares on the open market in 2014, and has not bought since 2014. Sales in 2 of the 13 years since 2014.
In SEC filings since 2014: the latest open-market purchase is from 2014; the latest open-market sale is from 2016.
Amgen (AMGN), from 2014 to 2016: 1 purchase and 2 sales.
Robert A Bradway reported 1 open-market purchase and 2 sales here, 2014 to 2016.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.